The CDCap™ AML MRD Panel is specifically designed for adult Acute Myeloid Leukemia (AML) MRD research. Built upon liquid-phase hybridization target enrichment technology, this solution enables sensitive and reliable detection of residual disease through comprehensive mutation profiling.
This panel covers approximately 42.5 kb of the genome, targeting 32 genes. It enables enrichment of various types of mutation information, including base substitutions, insertions/deletions, and gene fusions, making it suitable for MRD monitoring. When combined with the complete optional library preparation workflow, the solution demonstrates exceptional performance for high-throughput sequencing applications.
Precise Coverage
· ~90% of cases harbor mutations, with ~60% of cases exhibiting three or more mutations.
Low Background Noise
· Delivers accurate and reliable results with a high signal-to-noise ratio.
Higher Sensitivity
· Achieves lower detection limits through high conversion efficiency.
Stable and Efficient
· Avoids inconsistent sequencing data and reduces rework.
| Enrichment Method: | Probe Hybridization Capture |
| Species: | Human |
| Variant Types: | SNV、Indel、Fusion |
| Target Size: | 42.5Kb |
| Cancer Type: | AML |
| Number of Genes: | 32 |
| Sample Type: | blood,Bone Marrow etc. |
| Input DNA/RNA: | >30ng |
| Method: | NGS |
| Sequencing Platform: | Illumina |
| Storage: | Store at -20 °C. |
1、Capture performance
2、Analysis of mutation in standard
| ASXL1 | BRINP3 | CBL | CEBPA* | DNMT3A | EZH2 | FLT3 | GATA2 |
| HNRNPK | IDH1 | IDH2 | JAK2 | KIT | KMT2A† | KRAS | MYH11† |
| NPM1 | NRAS | PHF6* | PTEN | PTPN11 | RAD21* | RUNX1* | SF3B1 |
| SMC1A | SMC3 | SRSF2 | STAG2 | TET2* | TP53* | U2AF1 | WT1 |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
